Trial in progress: linvoseltamab, a BCMAxCD3 bispecific antibody, in a Phase 1b multi-cohort study of combination regimens for patients with relapsed/refractory multiple myeloma

被引：0
|
作者：
Rodriguez-Otero, Paula [1 ]
Joseph, Nisha [2 ]
Kumar, Shaji [3 ]
Leleu, Xavier [4 ]
Manier, Salomon [5 ]
Dimopoulos, Meletios [6 ]
Mateos, Maria-Victoria [7 ]
Oriol, Albert [8 ,9 ]
Bumma, Naresh [10 ]
Gong, Weiying [11 ]
Roy, Pourab [11 ]
Lorenc, Karen Rodriguez [11 ]
Kroog, Glenn [11 ]
Sarkaria, Shawn [11 ]
机构：
[1] Univ Navarra Clin, CIMA, CIBERONC, IDISNA, Pamplona, Spain
[2] Emory Univ, Winship Canc Inst, Atlanta, GA USA
[3] Mayo Clin, Rochester, MN USA
[4] Hosp Mileterie, Poitiers, France
[5] Univ Lille, Ctr Hosp Univ Lille, Lille, France
[6] Natl & Kapodistrian Univ Athens, Athens, Greece
[7] Univ Hosp Salamanca, IBSAL, CIC, CIBERONC, Salamanca, Spain
[8] Catalan Inst Oncol, Hosp Germans Trias i Pujol, Badalona, Spain
[9] Josep Carreras Inst, Hosp Germans Trias i Pujol, Badalona, Spain
[10] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA
[11] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-046
引用
收藏
页码：S60 / S60
页数：1
相关论文
共 50 条
  • [41] A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes
    Zeidan, Amer M.
    Borate, Uma
    Pollyea, Daniel A.
    Brunner, Andrew M.
    Roncolato, Fernando
    Garcia, Jacqueline S.
    Filshie, Robin
    Odenike, Olatoyosi
    Watson, Anne Marie
    Krishnadasan, Ravitharan
    Bajel, Ashish
    Naqvi, Kiran
    Zha, Jiuhong
    Cheng, Wei-Han
    Zhou, Ying
    Hoffman, David
    Harb, Jason G.
    Potluri, Jalaja
    Garcia-Manero, Guillermo
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (02) : 272 - 281
  • [42] A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody).
    Rodriguez-Otero, Paula
    D'Souza, Anita
    Reece, Donna Ellen
    van de Donk, Niels W. C. J.
    Chari, Ajai
    Krishnan, Amrita Y.
    Martin, Thomas G.
    Mateos, Maria-Victoria
    Morillo, Daniel
    Hurd, David Duane
    Rosinol, Laura
    Balari, Anna Sureda
    Wasch, Ralph
    Vishwamitra, Deeksha
    Lin, Shun Xin Wang
    Prior, Thomas
    Vandenberk, Lien
    Smit, Marie-Anne Damiette
    Rocafiguera, Albert Oriol
    Dholaria, Bhagirathbhai R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [43] Trial in Progress: Phase 1b/2 Open-Label Study of Lisaftoclax (APG-2575) Monotherapy or in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (R/R MM)
    Fu, Chengcheng
    Chen, Zi
    Li, Wensi
    Men, Lichuang
    Wu, Depei
    Yang, Dajun
    Zhai, Yifan
    BLOOD, 2021, 138
  • [44] Efficacy and Safety of ABBV-383, a BCMA Bispecific Antibody, in Black Patients With Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis of a Phase 1 Trial
    D'Souza, Anita
    Rodriguez-Valdes, Cesar
    Kumar, Shaji
    Chung, Alfred
    Tuchman, Sascha
    Safah, Hana
    Weisel, Katja
    Teipel, Raphael
    Korde, Neha
    Vij, Ravi
    Bueno, Orlando
    Rosenberg, Tanya
    Pothacamury, Rajvineeth
    Polepally, Akshanth
    Ahsan, Aarif
    Lee, Shane
    Jin, Ziyi
    Spence, Shelli
    Talati, Chetasi
    McKay, John
    Voorhees, Peter M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S48 - S48
  • [45] Oncolytic Reovirus Immune Priming: A Phase 1b Study of Reolysin with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Kelly, Kevin R.
    Wu, Kaijin
    Tsao-Wei, Denice
    Groshen, Susan
    Triche, Timothy Junius, Jr.
    Mohrbacher, Ann
    Chang, Grace
    Fernando, Donna
    Siddiqi, Imran N.
    Coffey, Matt
    Gill, George
    Lee, Amy
    Carew, Jennifer S.
    Nawrocki, Steffan T.
    BLOOD, 2016, 128 (22)
  • [46] Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma
    Seggewiss-Bernhardt, Ruth
    Bargou, Ralf C.
    Goh, Yeow Tee
    Stewart, A. Keith
    Spencer, Andrew
    Alegre, Adrian
    Blade, Joan
    Ottmann, Oliver G.
    Fernandez-Ibarra, Cristina
    Lu, Hong
    Pain, Scott
    Akimov, Mikhail
    Iyer, Swaminathan Padmanabhan
    CANCER, 2015, 121 (13) : 2185 - 2192
  • [47] A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)
    Gasparetto, Cristina
    Schiller, Gary J.
    Callander, Natalie Scott
    Lentzsch, Suzanne
    Tuchman, Sascha A.
    Bahlis, Nizar
    White, Darrell J.
    Chen, Christine I.
    Sutherland, Heather J.
    Baljevic, Muhamed
    Kotb, Rami
    Leblanc, Richard
    Sebag, Michael
    Venner, Christopher P.
    Bensinger, William I.
    Sheehan, Heidi
    Chai, Yi
    Kai, Kazuharu
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    Lipe, Brea C.
    BLOOD, 2019, 134
  • [48] A Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Kumar, Shaji
    Harrison, Simon J.
    Cavo, Michele
    De La Rubia, Javier
    Popat, Rakesh
    Gasparetto, Cristina J.
    Hungria, Vania
    Salwender, Hans J.
    Suzuki, Kenshi
    Kim, Inho
    Punnoose, Elizabeth
    Hong, Wan-Jen
    Freise, Kevin J.
    Sood, Anjla
    Jalaluddin, Muhammad
    Ross, Jeremy
    Ward, James E.
    Maciag, Paulo
    Moreau, Philippe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E31 - E31
  • [49] Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study
    Richardson, Paul G.
    Chanan-Khan, Asher A.
    Lonial, Sagar
    Krishnan, Amrita Y.
    Carroll, Michael P.
    Alsina, Melissa
    Albitar, Maher
    Berman, David
    Messina, Marianne
    Anderson, Kenneth C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 153 (06) : 729 - 740
  • [50] A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia
    Christine E. Ryan
    Danielle M. Brander
    Paul M. Barr
    Svitlana Tyekucheva
    Liam R. Hackett
    Mary C. Collins
    Stacey M. Fernandes
    Yue Ren
    Yinglu Zhou
    Mikaela M. McDonough
    Heather A. Walker
    Monica R. McEwan
    Jeremy S. Abramson
    Eric D. Jacobsen
    Ann S. LaCasce
    David C. Fisher
    Jennifer R. Brown
    Matthew S. Davids
    Leukemia, 2023, 37 : 835 - 842
12345